Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

David Tsai Ting

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3261-2322; OpenAlex author ID A5012704679; NIH RePORTER profile ID 10310446. Sources: funder_awards.

Their work

Papers
39 (first author 0, last author 4)
Trials
0
Grants
4
Labs led
1
Collaborators
171
Papers, trials and grants by year

2009: 1 grant · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 1 grant · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 5 papers · 2021: 5 papers · 2022: 7 papers · 2023: 1 grant · 2024: 7 papers · 2025: 4 papers · 2026: 3 papers, 1 grant

Papers 39

  1. Disparities in the diagnosis and management of exocrine pancreatic insufficiency in resectable vs metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag084↗
  2. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2052↗
  3. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  4. Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer. Co-author DOI 10.1038/s41556-025-01697-8↗
  5. The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Co-author DOI 10.1101/2025.08.26.672505↗
  6. LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2159-8290.cd-24-1317↗
  7. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  8. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
  9. Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. Last author DOI 10.1016/j.cell.2024.09.024↗
  10. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  11. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  12. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Co-author DOI 10.1158/1078-0432.ccr-23-3841↗
  13. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  14. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  15. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2022.04.014↗
  16. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  17. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. Co-author DOI 10.1073/pnas.2209563119↗
  18. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  19. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  20. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  21. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  22. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  23. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  24. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  25. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  26. Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Co-author DOI 10.1158/1078-0432.ccr-20-4712↗
  27. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  28. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗
  29. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  30. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  31. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  32. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  33. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Last author DOI 10.1016/j.cell.2019.05.012↗
  34. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-018-0196-2↗
  35. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Last author DOI 10.1073/pnas.1914915116↗
  36. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Co-author DOI 10.18632/oncotarget.20833↗
  37. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-016-3108-0↗
  38. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biomaterials.2016.03.044↗
  39. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗

Grants 4

  1. High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗
  2. Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression R01CA235412↗
  3. Circulating Tumor Cells to Assess Pancreatic Cancer Disease Status AWARD pancan:2014-david-ting-md-circulating-tumor-cells-to-assess-pancre
  4. Characterizing Circulating Tumor Cells in Pancreatic Cancer AWARD pancan:2009-david-t-ting-md-characterizing-circulating-tumor-cells-i

Closest collaborators

The 25 strongest of 171 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 16 shared papers, 1 shared grant, 2015–2026 · strength 2.56
  2. William L. Hwang · 6 shared papers, 1 shared grant, 2020–2026 · strength 1.70
  3. Colin D. Weekes · 12 shared papers, 2019–2026 · strength 1.62
  4. David P. Ryan · 14 shared papers, 2015–2026 · strength 1.39
  5. Vikram Deshpande · 15 shared papers, 2015–2024 · strength 1.35
  6. Keith D. Lillemoe · 13 shared papers, 2015–2025 · strength 1.29
  7. Jennifer Yon-Li Wo · 12 shared papers, 2015–2026 · strength 1.28
  8. Carlos F. Fernandez-del Castillo · 12 shared papers, 2015–2025 · strength 1.24
  9. Aparna R. Parikh · 8 shared papers, 2019–2026 · strength 1.03
  10. Motaz Qadan · 9 shared papers, 2019–2024 · strength 1.02
  11. Andrew Scott Liss · 9 shared papers, 2019–2025 · strength 1.01
  12. Andrew Louis Warshaw · 9 shared papers, 2015–2025 · strength 0.92
  13. Mari A. Mino-Kenudson · 7 shared papers, 2020–2025 · strength 0.91
  14. Samuel Jacob Klempner · 1 shared grant, 2026 · strength 0.86
  15. Cristina Rosa Ferrone · 10 shared papers, 2015–2024 · strength 0.86
  16. Carlos Fernández-del Castillo · 6 shared papers, 2019–2026 · strength 0.75
  17. Lei Zheng · 5 shared papers, 2021–2024 · strength 0.66
  18. Hannah Johnson Roberts · 4 shared papers, 2024–2026 · strength 0.64
  19. Raul Mostoslavsky · 1 shared grant, 2023 · strength 0.61
  20. NABEEL El-BARDEESY · 1 shared grant, 2023 · strength 0.61
  21. Richard Andrew Burkhart · 5 shared papers, 2020–2024 · strength 0.58
  22. Elizabeth M. Jaffee · 5 shared papers, 2020–2024 · strength 0.58
  23. Jacquelyn W. Zimmerman · 5 shared papers, 2020–2024 · strength 0.58
  24. Lawrence Scott Blaszkowsky · 5 shared papers, 2015–2026 · strength 0.57
  25. Jimmy A. Guo · 4 shared papers, 2020–2025 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.